Aarti Drugs is currently trading at Rs. 406.65, up by 9.25 points or 2.33% from its previous closing of Rs. 397.40 on the BSE.

The stock opened at Rs. 399.65 and has touched a high of Rs. 408.95 and a low of Rs. 394.00 so far. A total of 5,025 shares have been traded on the counter.

The BSE group 'A' stock, with a face value of Rs. 10, reached a 52-week high of Rs. 634.90 on August 27, 2024, and a 52-week low of Rs. 388.00 on January 28, 2025. Over the past week, the stock has traded between Rs. 416.35 and Rs. 388.00. The company’s current market capitalization stands at Rs. 3,695.98 crore.

Promoters hold a 55.38% stake in the company, while Institutions and Non-Institutions hold 11.05% and 33.57%, respectively.

Meanwhile, Aarti Drugs’ board has approved an investment of up to Rs. 25 crore in equity shares of Pinnacle Life Science, its wholly-owned subsidiary, through a Rights Issue. The investment will be utilized for Pinnacle’s expansion, capex plans, and general corporate purposes. The decision was approved in the company’s board meeting held on January 29, 2025.

Aarti Drugs is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals, and also produces formulations through its subsidiary, Pinnacle Life Science.